A subscription to JoVE is required to view this content. Sign in or start your free trial.

Method Article

Generation of Induced Pluripotent Stem Cells from Muscular Dystrophy Patients: Efficient Integration-free Reprogramming of Urine Derived Cells

10.6K views

⸱

DOI:

10.3791/52032

⸱

January 28th, 2015

 , 

In This Article

Summary

This protocol entails detailed procedures for isolation of urine derived cells from muscular dystrophy patients; their efficient and rapid reprogramming through Sendai virus transduction.

Abstract

Dystrophic cardiomyopathy is a poorly understood consequence of muscular dystrophy. Generating induced Pluripotent Stem Cells (iPSCs) from patients with muscular dystrophy is an invaluable cellular source for in vitro disease model systems and can be used for drug screening studies. Patient-derived urine cells have been used in successful reprogramming into induced pluripotent stem cells in order to model dystrophic cardiomyopathy1. Addressing the safety concerns of integrating vector systems, we present a protocol using a non-integrating Sendai virus vector for transduction of Yamanaka factors into urine cells collected from patients with muscular dystrophy. This protocol generates fully reprogrammed clones within 2–3 weeks. The pluripotent cells are vector-free by passage-13. These dystrophic iPSCs can be differentiated into cardiomyocytes and used either to study disease mechanisms or for drug screening.

Introduction

Cardiomyopathy is the second leading cause of death in patients with Duchenne and Becker muscular dystrophy (MD). Although mutations in the X-linked dystrophin gene occur in 1:3,500 male births, very little is known about the molecular and cellular events leading to progressive cardiac muscle damage. Human induced pluripotent stem cells derived from muscular dystrophy patients have emerged as a novel tool to study the underlying disease mechanisms and to use for drug screening1,2.

The anticipated discomfort of skin biopsies or blood samples may dissuade young patients and/or their guardians to give consent for study participation....

Access restricted. Please log in or start a trial to view this content.

Protocol

NOTE: Patients and/or their guardians should give informed consent to participate in an Institutional Review Board approved study.

1. Buffers and Media Preparations

  1. Washing buffer: To prepare 100 ml of washing buffer, add 1 ml of 100x pen/strep Solution (100 U/ml penicillin + 100 µg/ml of Streptomycin) to 99 ml of phosphate buffer saline (PBS).
  2. Urinary Progenitor Cell (UPC) Medium: To prepare UPC medium, mix equal volumes of Keratinocyte Serum Free (KSF) Medium + Progenitor Cell Medium.
    1. KSF Medium: To prepare keratinocyte medium, add 5 ng/ml of epidermal growth factor (EGF), 50 ng/ml of bovine pituitar....

Access restricted. Please log in or start a trial to view this content.

Results

Most progenitor cells isolated from human urine are positive for uroepithelial progenitor and pericyte markers such as CD44, CD73, and CD146 (97.37%, 97.09%, and 97.3% respectively; Figure 1A and 1B). These cells also expressed other mesenchymal markers such as alpha-smooth muscle actin and vimentin (Figure 1B). RT-PCR analysis gives evidence of a mixed population of cells in the cultures in that there is weak expression of Cytokeratin-7 (CK-7) and Uroplakin (UP)-Ia &.......

Access restricted. Please log in or start a trial to view this content.

Discussion

Modeling cardiovascular diseases using iPSCs is becoming a common approach to understand the genetic contribution4-6. Some unanticipated difficulties of obtaining cell samples from patients, especially young children, can be avoided by offering the option of a non-invasive approach such as a urine collection. In this young patient population, it is often difficult to collect a volume of urine sufficient to yield enough urine cells for reprogramming. Coaching the young patients to drink fluids 30 min prior to t.......

Access restricted. Please log in or start a trial to view this content.

Disclosures

The authors declare that they have no competing financial interests.

Acknowledgements

Development of this protocol was supported by the Advancing a Healthier Wisconsin and the National Center for Advancing Translational Sciences, National Institutes of Health, through Grant Number 8UL1TR000055. Its contents are solely the responsibility of the authors and do not necessarily represent the official views of the NIH.

....

Access restricted. Please log in or start a trial to view this content.

Materials

List of materials used in this article
NameCompanyCatalog NumberComments
Materials
4 Oz. Specimen Cup with LidSTL Medical SupplyM9AMSAS340For Urine Sample Collection
15 ml BD-Falcon TubesFisher Scientific352097
50 ml BD-Falcon TubesFisher Scientific352098
Round Glass CoverslipsFisher Scientific12-545-81
CytoTune-iPS Sendai Reprogramming KitLife TechnologiesA1378-001
PBS, pH 7.4Life Technologies10010-023
Pen-Strep w/o Glutamine Life Technologies15140-122Warm in 37 °C water bath before use
RPMI Medium 1640Life Technologies11875-093Warm in 37 °C water bath before use
B-27 Supplement w/Insulin (50x)Life Technologies17504-044Warm in 37 °C water bath before use
B-27 Supplement w/o Insulin (50x)Life Technologies0050129SAWarm in 37 °C water bath before use
DMEM/F12 (1:1)Life Technologies11330-032Warm in 37 °C water bath before use
Versene, 1:5,000Life Technologies15040066Warm in 37 °C water bath before use
bFGF (10 µg)Life Technologies13256-029Warm in 37 °C water bath before use
Cell Counter CartridgesLife TechnologiesC10228
Knockout Serum (500 ml Bottle)Life Technologies10828-028Warm in 37 °C water bath before use
Recovery Cell Culture Freezing MediumLife Technologies12648-010
Keratinocyte-SFM (1x), LiquidLife Technologies17005-042Warm in 37 °C water bath before use
DMEM, High Glucose, GlutamaxLife Technologies10566-016Warm in 37 °C water bath before use
Ham's F-12 Nutrient Mix Life Technologies11765-054Warm in 37 °C water bath before use
EGF Recombinant Human Protein, Liquid FormLife TechnologiesPHG0311LWarm in 37 °C water bath before use
Insulin, Human Recombinant, Zinc SolnLife Technologies12585-014Warm in 37 °C water bath before use
TeSR-E8Stem Cell Technologies5940Warm in 37 °C water bath before use
ROCK Inhibitor (Y-27632)SelleckS1049Warm in 37 °C water bath before use
MatrigelBD Biosciences354277hESC Qualified Matrix, LVED Free
RNeasy Mini Kit Qiagen74104
iScript cDNA Synthesis KitBio-Rad170-8890
DreamTaq Green PCR Master Mix (2x)Thermo-ScientificK1081
FBS-QualifiedSigma AldrichF6178Warm in 37 °C water bath before use
Adenine BioreagentSigma AldrichA2786-5GWarm in 37 °C water bath before use
Cholera Toxin from Vibrio choleraeSigma AldrichC8052-.5MGWarm in 37 °C water bath before use
HydrocortisoneSigma AldrichH0888-1GWarm in 37 °C water bath before use
Holo-transferrin from humanSigma AldrichT0665-50MGWarm in 37 °C water bath before use
3,3',5-Triiodo-L-thyronine sodium saltSigma AldrichT6397-100MGWarm in 37 °C water bath before use
DAPI Santa Cruz BiotechnologySC-3598
Fluoromount Aquous mounting mediumSigma AldrichF4680
16% ParaformaldehydeAlfa-Aesar43368
Antibodies
Mouse anti CD44 - labeled with FITC BD Biosciences560977
Mouse anti CD146 - labeled with PEBD Biosciences561013
Mouse anti CD73 - labeled with PEBD Biosciences561014
Mouse anti-α-smooth muscle actinSigma AldrichA2547
Mouse anti-VimentinAbcamab8978-100
Mouse Anti - TRA-1-81Life Technologies411100
Rabbit anti Oct 3/4Santa Cruz BiotechnologySC-9081
Mouse Anti DystrophinLeica BiosystemsNCL-DYSB

References

  1. Guan, X., et al. Dystrophin-deficient cardiomyocytes derived from human urine: New biologic reagents for drug discovery. Stem Cell Research. 12 (2), 467-480 (2014).
  2. Dick, E., et al.

Access restricted. Please log in or start a trial to view this content.

Reprints and Permissions

Explore More Articles

Sendai Virus ReprogrammingIntegration Free MethodYamanaka Factors TransductionPluripotency ConfirmationFlow Cytometric AnalysisReverse Transcriptase PCRCardiomyocyte Differentiation